Saama Technologies and ICON Partner to Unlock the Value of RWE
Saama Technologies, a clinical and health data analytics company, and ICON plc, a global provider of drug development and commercialization solutions and services, have partnered to accelerate the use of Real World Evidence across the product lifecycle and drive mission critical decisions for medical affairs, reimbursement, and commercialization functions.
Read the full release here.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
STEP UP Trial Shows Semaglutide 7.2 mg Achieves Superior Weight Loss vs. 2.4 mg, Placebo
January 17th 2025Semaglutide 7.2 mg significantly outperformed semaglutide 2.4 mg and placebo with a 20.7% average reduction in weight and a comparable safety and tolerability profile, further establishing its efficacy in obesity treatment.
